ATE318588T1 - Verwendung von einem verstärker der glukosen aufnahme zur verminderung postischämischen herzschädigungen - Google Patents

Verwendung von einem verstärker der glukosen aufnahme zur verminderung postischämischen herzschädigungen

Info

Publication number
ATE318588T1
ATE318588T1 AT99934911T AT99934911T ATE318588T1 AT E318588 T1 ATE318588 T1 AT E318588T1 AT 99934911 T AT99934911 T AT 99934911T AT 99934911 T AT99934911 T AT 99934911T AT E318588 T1 ATE318588 T1 AT E318588T1
Authority
AT
Austria
Prior art keywords
schaemic
glucose uptake
reduce post
heart injury
uptake enhancer
Prior art date
Application number
AT99934911T
Other languages
English (en)
Inventor
Antoine Michel A Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Glaxosmithkline Lab Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Application filed by Smithkline Beecham Plc, Glaxosmithkline Lab Sas filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE318588T1 publication Critical patent/ATE318588T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT99934911T 1998-07-21 1999-07-21 Verwendung von einem verstärker der glukosen aufnahme zur verminderung postischämischen herzschädigungen ATE318588T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound

Publications (1)

Publication Number Publication Date
ATE318588T1 true ATE318588T1 (de) 2006-03-15

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99934911T ATE318588T1 (de) 1998-07-21 1999-07-21 Verwendung von einem verstärker der glukosen aufnahme zur verminderung postischämischen herzschädigungen

Country Status (35)

Country Link
EP (2) EP1098638B1 (de)
JP (1) JP2002521325A (de)
KR (1) KR20010079550A (de)
CN (1) CN1167416C (de)
AP (1) AP1416A (de)
AR (1) AR020614A1 (de)
AT (1) ATE318588T1 (de)
AU (1) AU5053599A (de)
BG (1) BG105251A (de)
BR (1) BR9912144A (de)
CA (1) CA2338216A1 (de)
CO (1) CO5060465A1 (de)
CY (1) CY1106078T1 (de)
CZ (1) CZ2001250A3 (de)
DE (1) DE69930125T2 (de)
DK (1) DK1098638T3 (de)
DZ (1) DZ2854A1 (de)
EA (1) EA004772B1 (de)
ES (1) ES2259839T3 (de)
GC (1) GC0000173A (de)
HU (1) HUP0103870A3 (de)
ID (1) ID27850A (de)
IL (1) IL140741A0 (de)
MA (1) MA26662A1 (de)
NO (1) NO20010293L (de)
NZ (1) NZ509175A (de)
OA (1) OA11583A (de)
PE (1) PE20000881A1 (de)
PL (1) PL345663A1 (de)
PT (1) PT1098638E (de)
SI (1) SI1098638T1 (de)
SK (1) SK1022001A3 (de)
TR (1) TR200100208T2 (de)
TW (2) TW200307532A (de)
WO (1) WO2000004889A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
CN1592620A (zh) * 2000-06-16 2005-03-09 史密斯克莱·比奇曼公司 与心脏胰岛素抵抗相关的疾病的治疗和预防方法
EP1435894A4 (de) 2001-07-23 2005-07-06 Galileo Pharmaceuticals Inc Zytoprotektive verbindungen, pharmazeutische und kosmetische formulierungen und verfahren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
KR20000036035A (ko) * 1996-09-12 2000-06-26 가와무라 요시부미 트로글리타존을 함유하는 글루타티온 환원효소 활성증강제
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
KR20010079550A (ko) 2001-08-22
EP1098638B1 (de) 2006-03-01
DE69930125T2 (de) 2006-10-05
CO5060465A1 (es) 2001-07-30
TW200307532A (en) 2003-12-16
CA2338216A1 (en) 2000-02-03
DE69930125D1 (de) 2006-04-27
HUP0103870A3 (en) 2003-06-30
NO20010293D0 (no) 2001-01-18
PL345663A1 (en) 2002-01-02
EP1523980A2 (de) 2005-04-20
EP1098638A1 (de) 2001-05-16
EA004772B1 (ru) 2004-08-26
PE20000881A1 (es) 2000-10-07
OA11583A (en) 2004-07-01
BG105251A (en) 2001-10-31
EA200100164A1 (ru) 2001-08-27
JP2002521325A (ja) 2002-07-16
BR9912144A (pt) 2001-04-03
DK1098638T3 (da) 2006-06-19
CZ2001250A3 (cs) 2002-03-13
CN1167416C (zh) 2004-09-22
HUP0103870A2 (hu) 2002-05-29
NZ509175A (en) 2003-10-31
DZ2854A1 (fr) 2003-12-01
PT1098638E (pt) 2006-07-31
NO20010293L (no) 2001-03-07
AP1416A (en) 2005-06-13
EP1523980A3 (de) 2009-03-18
AU5053599A (en) 2000-02-14
SI1098638T1 (sl) 2006-06-30
GC0000173A (en) 2006-03-29
WO2000004889A1 (en) 2000-02-03
IL140741A0 (en) 2002-02-10
MA26662A1 (fr) 2004-12-20
TWI239836B (en) 2005-09-21
TR200100208T2 (tr) 2001-05-21
SK1022001A3 (en) 2001-08-06
AP2001002033A0 (en) 2001-03-31
AR020614A1 (es) 2002-05-22
CY1106078T1 (el) 2011-06-08
CN1310619A (zh) 2001-08-29
ID27850A (id) 2001-04-26
ES2259839T3 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
DE69504180D1 (de) Bestimmung des genesungszustandes von knochen nach fraktur
DE69813935D1 (de) Verwendung von Retinoiden zur Induzierung von Hautpigmentierung
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE19680859T1 (de) Verwendung von Vitamin C oder seiner Derivate oder Analoga zur Stimulierung der Synthese von Haut-Elastin
DE69827245D1 (de) Ohrteil zur unterdrückung von lärm
DE69227545D1 (de) Oximeter zur zuverlässigen klinischen Bestimmung der Blutsauerstoffsättigung in einem Fötus
DE60017103D1 (de) Bestimmung der orientierung von elektrokardiogramm-signalen
DE69839259D1 (de) Anordnung von leitungen zum herzen
ATE234554T1 (de) Verwendung von koniferylaldehyd und alpha-hexyl cinnamaldehyd zur bekämpfung von insekten und milben
DE69430731D1 (de) Implantierbarer herzschrittmacher zur beendigung von herzarrhythmie
DE60211632D1 (de) Verwendung von Cyclotetrasaccharide zur Erhöhung der "Aktiven-Sauerstoff-Eliminierenden-Aktivität"
DE69702862D1 (de) Verwendung von sulfatierten polysacchariden zur behandlung einer chronischer verletzung
ATE318588T1 (de) Verwendung von einem verstärker der glukosen aufnahme zur verminderung postischämischen herzschädigungen
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
DE69816521D1 (de) Wasserfreie kosmetische Zusammensetzung mit Ceramiden zur Förderung der Festigkeit der Haut
DE69707163T2 (de) Klebstoffe, beständig gegen Hautpenetrationsförderer
DE69730451D1 (de) Kassette zur aufnahme von flachen artikeln
DE59811053D1 (de) Verwendung von Bienenwachs zur Verstärkung der UV-A-Schutzleistung kosmetischer oder dermatologischer Formulierungen
DE69828492D1 (de) Verwendung von isothiazolone zur reduzierung von emissionen von hcn
DE69702817D1 (de) Verwendung von N-Acetonylbenzamiden zur Bekämpfung von resistenten Pilzen
DE69801883T2 (de) Sauerstoff- und stickstoffhinzufügung zur erhöhung der ausbeute der herstellung von ammonia
DE59510372D1 (de) Verwendung von bio-assimilierbaren wässrigen borverbindungen zur bekämpfung subviröser krankheitserreger
DE60336549D1 (de) Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
AT380636B (de) Rotationspumpe zur verwendung als blut- und herzpumpe
DE69801806T2 (de) Verwendung von crotalus viridis helleri venom zur bestimmung von aktiviertem protein c reaktivität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1098638

Country of ref document: EP

REN Ceased due to non-payment of the annual fee